Zai Lab Limited (HKG:9688)
14.63
+0.15 (1.04%)
Jan 21, 2026, 3:05 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $116.10M USD in the quarter ending September 30, 2025, with 13.52% growth. This brings the company's revenue in the last twelve months to $441.63M, up 24.14% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$441.63M
Revenue Growth
+24.14%
P/S Ratio
4.77
Revenue / Employee
$236.29K
Employees
1,869
Market Cap
16.40B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | 129.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.74B |
| InnoCare Pharma | 1.56B |
| Keymed Biosciences | 955.73M |
| Everest Medicines | 932.82M |
| HBM Holdings | 908.35M |
| Lepu Biopharma | 767.54M |
| Ascentage Pharma Group International | 428.02M |
| Mirxes Holding Company | 166.32M |
Zai Lab News
- 5 days ago - Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 7 days ago - Zai Lab Ltd at JPMorgan Healthcare Conference Transcript - GuruFocus
- 7 days ago - Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 14 days ago - Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - Business Wire
- 15 days ago - Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 16 days ago - After-Hours Gainers: GH Research, Phathom, Forte, OKYO, Zai Lab, LifeMD, Werewolf & Corvus Rally - Nasdaq
- 4 weeks ago - Zai Lab Receives Approval In China For Schizophrenia Drug COBENFY - Nasdaq